Assessment of Erythroid and Granulocytic Hematopoietic Lineages in Patients with Non-Small-Cell Lung Carcinoma
- 作者: Goldberg V.1, Polyakova T.2,3, Popova N.1, Vysotskaya V.1, Simolina E.1, Belevich Y.1, Tuzikova T.1, Goldberg A.1, Zhdanov V.2, Miroshnichenko L.2, Udut E.2, Simanina E.2, Dygai A.2, Zyuz’kov G.2
-
隶属关系:
- Research Institute of Oncology, Tomsk National Research Medical Center
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
- National Research Tomsk State University
- 期: 卷 163, 编号 4 (2017)
- 页面: 469-474
- 栏目: Oncology
- URL: https://journals.rcsi.science/0007-4888/article/view/239000
- DOI: https://doi.org/10.1007/s10517-017-3830-y
- ID: 239000
如何引用文章
详细
The toxic effects of combined cisplatin/docetaxel therapy cycles on erythroid and granulocytic hematopoietic lineages as well as their intercycle recovery were examined in patients with stage III-IV non-small-cell lung carcinoma. Responsiveness of the blood system to this therapy remained at a high level. Combined therapy pronouncedly activated the key elements of the erythroid and granulocytic hematopoietic lineages leading to accumulation of immature and mature myelokaryocytes in the bone marrow, enlargement of the medullary pool of mature neutrophils, and increase in the count of medullary erythroid and granulocytic precursor cells under conditions of their accelerated maturation.
作者简介
V. Goldberg
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
T. Polyakova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine; National Research Tomsk State University
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk; Tomsk
N. Popova
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
V. Vysotskaya
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
E. Simolina
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
Yu. Belevich
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
T. Tuzikova
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
A. Goldberg
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
V. Zhdanov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
L. Miroshnichenko
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
E. Udut
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
E. Simanina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
A. Dygai
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
G. Zyuz’kov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
编辑信件的主要联系方式.
Email: zgn@pharmso.ru
俄罗斯联邦, Tomsk
![](/img/style/loading.gif)